Overview

Absolute Bioavailability Study With Bexagliflozin

Status:
Withdrawn

Trial end date:
2018-09-16

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the absolute bioavailability of bexagliflozin following a single oral dose co-administered with an intravenous dose.

Phase:

Phase 1

Details

Lead Sponsor:

Theracos

Treatments:

Bexagliflozin